METiS Therapeutics integrates drug discovery and delivery using AI, machine learning and quantum simulation to develop optimized therapies for patients with serious diseases. Its proprietary AiTEM platform combines data-driven AI algorithms, mechanism-driven quantum mechanics and molecular dynamics simulations to calculate API properties, elucidate API-target and API-excipient interactions, and predict chemical, physical and pharmacokinetic properties in specific microenvironments. The platform is intended to enable efficient lead optimization, candidate selection and formulation design for small molecule and nucleic acid therapeutics. Founded by a team of MIT researchers, serial entrepreneurs and biotech industry veterans, METiS develops and in-licenses novel assets that could benefit from its data-driven platform. The company launched with an $86 million Series A financing led by PICC PE and China Life, with participation from Sequoia Capital China, Lightspeed, 5Y Capital, FreeS Fund and CMBI Zhaoxin Wuji Fund. METiS will use the financing to advance its pipeline of novel assets and continue development of its AI-driven drug discovery and delivery platform.

Total raised

$86M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2021